Lantus and cancer
June 12, 2012
SANOFI’S Lantus diabetes drug
(insulin glargine [rDNA origin]
injection), does not increase the
risk of cancer compared with other
insulins, according to the results of
a large-scale epidemiological study.
The study is the largest of its kind,
and involved 447,821 patients using
insulin and over 1.5 million
person-years of observation.
According to the study there was
no evidence of an increased risk of
breast cancer in women (HR: 1.12;
95% CI: 0.99-1.27), prostate cancer
in men (HR: 1.11; 95% CI: 1.00-1.24)
and colorectal cancer in men and
women (HR: 0.86, 95% CI: 0.76-
0.98) in users of insulin glargine vs
other insulins.
In addition, the study found that
there was no evidence of an
increased risk in users of insulin
glargine vs other insulins relative to
the pre-specified secondary
hypothesis (risk of all forms of
cancer combined) and the
exploratory hypothesis (risk of lung
or pancreatic cancer).
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jun 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jun 12
